Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections.

Furthermore, because rates of this outcome in the SGLT-2 inhibitor group were lower for only 1 comparison (SGLT-2 inhibitors vs. glucagon-like peptide-1-receptor agonists) and in only 1 database (MarketScan), we cannot rule out the possibility of a chance finding. We agree that further data on the role of SGLT-2 inhibitors and risk for severe UTIs in patients with preexisting UTIs could provide additional useful clinical knowledge. 1 Puckrin R, Saltiel MP, Reynier P, et al, SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials Acta Diabetol,, 2018, 55, 503-14, 29484489.